Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: fundamental (50), essential (280), sweeping (2), thorough (35), far-reaching (2), extreme (113)

Annual-report-2018-19

Description: ANNUAL REPORT AND ACCOUNTS 2018/19 incorporating the quality account 2018/19 Presented to Parliament pursuant to Schedule 7, paragraph 25
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-2018-19.pdf

Durvalumab_14day

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (14 day) Regimen • NSCLC - Durvalumab (14 day) Indication • Stage 3 NSCLC after rad
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab-14day.pdf

Durvalumab(28day-1500mg)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) Indication • Durvalumab is i
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

InP RIVAC (66) cytarabine etoposide ifosfamide rituximab

Description: Chemotherapy Protocol LYMPHOMA CYTARABINE-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RIVAC) 66 years and above Inpatient Regimen Ther
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RIVAC-66-cytarabine-etoposide-ifosfamide-rituximab.pdf

InP RIVAC (65) cytarabine etoposide ifosfamide rituximab

Description: Chemotherapy Protocol LYMPHOMA CYTARABINE-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RIVAC) 65 years and below Inpatient Regimen There are mult
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RIVAC-65-cytarabine-etoposide-ifosfamide-rituximab.pdf

Cetuximab-Irinotecan (21day)

Description: Chemotherapy Protocol COLORECTAL CANCER CETUXIMAB-IRINOTECAN (21 day) This regimen may require funding Regimen • Colorectal C
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Cetuximab-Irinotecan.pdf

UHS Inclusion and Belonging Strategy

Description: Our strategy sets out clear actions we will take to make UHS a place where every person feels they belong and
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/uhs-inclusion-and-belonging-strategy.pdf

Finance and Performance Reports 2021-22 month 4 July 2021

Description: Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose Issue to be addressed: Finance Report 2021-22 Month 4 11.3 I
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2021-Trust-document/Finance-and-performance-reports/Finance-and-Performance-Reports-2021-22-Month-4-July-2021.pdf

Current funding calls

Description: Auto Generated Title Here you can find new grant funding calls from various funders. Links on the right will take you directly to other calls with specifi
Url: /ClinicalResearchinSouthampton/For-researchers/Grant-funding-support/Current-funding-calls/Current-funding-calls.aspx

Annual-report-24-25-final

Description: 2024/25 Incorporating the quality account University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2024/25 Presented to Parliament
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/Annual-report-24-25-final.pdf

21 to 30 of 32

Previous 1 2 3 4 Next